New Gate Capital

Investment decisions are led by Partners Alex Shilman and Rafael Kozlov, supported by a team of sector-specialist partners including Max Simonovsky (Head of Healthcare), Lidia Verra (Venture Partner), Josef Lapko (Head of North America), and Dima Shimelfarb (Impact Partner). Andrew Fine serves as CFO. The firm's website lists these individuals as its core leadership, suggesting a distributed rather than single-GP decision model.

New Gate Capital sources through its partner group's direct networks within Israel's deep-tech ecosystem and through Josef Lapko's North American presence. The firm's operator-partner model — where team members carry domain expertise rather than generalist investing backgrounds — points to relationship-driven origination among technical founders rather than auction-based deal flow.

The firm targets early-stage rounds, explicitly covering seed and start-up phases. Its own website describes it as an early-stage fund focused on tech from top Israeli founders. This positions New Gate Capital at the formation end of the venture spectrum, where capital is deployed before proven product-market fit.

The firm focuses on deep tech and maintains a dedicated healthcare vertical under Max Simonovsky. Beyond healthcare, its website emphasizes strong teams and deep technology. The Impact Partner role held by Dima Shimelfarb suggests some lens toward outcomes beyond pure financial returns, though no specific impact mandate has been published.

New Gate Capital operates as an asset manager and private equity firm, not a family office. Its early-stage venture posture does not appear tied to any single disclosed wealth origin. The firm's website and team structure are consistent with an independent venture fund rather than a family office or multi-family office.